{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:21:46Z","timestamp":1791390106046,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.drugalcdep.2018.02.023","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T16:24:42Z","timestamp":1523377482000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial"],"prefix":"10.1016","volume":"187","author":[{"given":"Adam","family":"Bisaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Andrew","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0010","series-title":"The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","author":"American Society of Addiction Medicine","year":"2015"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsat.2014.01.005","article-title":"A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence","volume":"46","author":"Bisaga","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended-release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.294.8.903","article-title":"Anesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial","volume":"294","author":"Collins","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0035","first-page":"CD004580","article-title":"Inpatient vs. other settings for detoxification for opioid dependence","author":"Day","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrneurol.2009.24","article-title":"Delirium in elderly adults Diagnosis, prevention and treatment","volume":"5","author":"Fong","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/10550887.2016.1189659","article-title":"Gender differences in treatment and clinical characteristics among patients receiving extended-release naltrexone","volume":"35","author":"Herbeck","year":"2016","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0060","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomized trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0065","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","article-title":"The mini international neuropsychiatric interview (MINI): a short diagnostic structured interview: reliability and validity according to the CIDI","volume":"12","author":"Lecrubier","year":"1997","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2014.02.002","article-title":"Extended-release naltrexone injection is performed in the majority of opioid-dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open-label trial","volume":"138","author":"Mannelli","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2012.08.027","article-title":"A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans","volume":"128","author":"Mitchell","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02599882","article-title":"Primary care-based ambulatory opioid detoxification: the results of a clinical trial","volume":"10","author":"O'Connor","year":"1995","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0095","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States: 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0105","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States: 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/clpt.2010.352","article-title":"Induction of opioid-dependent individuals onto buprenorphine and buprenorphine\/naloxone soluble-films","volume":"89","author":"Strain","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0120","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration SAMHSA","year":"2017"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/10550490500528464","article-title":"Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial","volume":"15","author":"Sullivan","year":"2006","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","article-title":"Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin","volume":"189","author":"Sullivan","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone vs. buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0140","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.113.209478","article-title":"A double-blind: within-subject comparison of spontaneous opioid withdrawal from buprenorphine vs. morphine","volume":"348","author":"Tompkins","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0376-8716(99)00033-2","article-title":"Naltrexone shortened opioid detoxification with buprenorphine","volume":"56","author":"Umbricht","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1360-0443.1988.tb02576.x","article-title":"Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers","volume":"83","author":"Vining","year":"1988","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.02.023_bib0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoact. Drugs"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618301856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618301856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T15:43:03Z","timestamp":1539618183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618301856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":34,"alternative-id":["S0376871618301856"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.02.023","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}